These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12370068)

  • 1. New approaches to raising the HDL cholesterol level.
    Shinkai H
    Mini Rev Med Chem; 2002 Jun; 2(3):271-6. PubMed ID: 12370068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1365-8. PubMed ID: 15461565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Curr Opin Lipidol; 2006 Aug; 17(4):394-8. PubMed ID: 16832162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
    Barter PJ; Brewer HB; Chapman MJ; Hennekens CH; Rader DJ; Tall AR
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):160-7. PubMed ID: 12588754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.
    Hourcade-Potelleret F; Laporte S; Lehnert V; Delmar P; Benghozi R; Torriani U; Koch R; Mismetti P
    Heart; 2015 Jun; 101(11):847-53. PubMed ID: 25872524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia.
    Inazu A; Mabuchi H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):291-7. PubMed ID: 12735230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
    Mabuchi H; Nohara A; Inazu A
    Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL elevation and lipid lowering therapy: current scenario and future perspectives.
    Chhabria MT; Suhagia BN; Brahmkshatriya PS
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):214-27. PubMed ID: 18221121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.